Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It is also involved in the provision of biological peptides, industrial hemp, and medical service business; and food and beverages, and cosmetics under the Hanhui, Xiao Lan, Ruyin Fangxing, and Ma Yuansu brands. The company was founded in 1980 and is based in Beijing, the People’s Republic of China.
Metrics to compare | 000813 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship000813PeersSector | |
---|---|---|---|---|
P/E Ratio | −378.0x | −13.3x | −0.5x | |
PEG Ratio | 2.70 | 0.02 | 0.00 | |
Price/Book | 1.9x | 4.1x | 2.6x | |
Price / LTM Sales | 21.4x | 5.5x | 3.3x | |
Upside (Analyst Target) | - | −12.8% | 45.4% | |
Fair Value Upside | Unlock | −12.7% | 7.7% | Unlock |